Xeris Pharmaceuticals | XERS - Net Income


Xeris Pharmaceuticals reported $621K in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Celltrion KRW 331.35B 270.18B Sep/2025
Cspc Pharmaceutical CNY 963.54M 106.35M Sep/2025
Deva Holding AS TRY 583.98M 319.1M Sep/2023
Dianthus Therapeutics USD -36.76M 5.13M Sep/2025
Divis Laboratories Ltd INR 5.83B 1.06B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Kangmei Pharma CNY -3.82M 12.21M Sep/2025
Knight Therapeutics CAD 85K 2.03M Sep/2024
Laboratorios Farma EUR 103.69M 37.04M Dec/2023
Malin Corporation EUR -1.1M 2.2M Dec/2023
Medical Developments International AUD -105K 409K Jun/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Neuren Pharmaceuticals AUD 7.52M 126.51M Jun/2025
Organigram Holdings CAD -37.96M 31.67M Sep/2025
Ovoca Bio EUR -5.65M 3.28M Jun/2022
Pacira USD 5.43M 10.28M Sep/2025
Perrigo USD 7.5M 15.9M Sep/2025
Pharma Mar EUR -4.1M 27.47M Sep/2025
Qiagen NV USD 107.83M 22.21M Dec/2025
Sartorius EUR 43.8M 11.3M Sep/2025
Sino Biopharmaceutical CNY 3.39B 2.91B Jun/2025
Supernus Pharmaceuticals USD -45.12M 67.62M Sep/2025
Tilray USD -44.93M 44.61M Sep/2025
Zz Pientze Pharmaceu CNY 687.04M 244.51M Sep/2025